Evaluation of the Rheumatoid Arthritis Observation of Biologic Therapy risk score in Japanese patients with rheumatoid arthritis starting first biologic disease–modifying antirheumatic drugs: A validation study using the Institute of Rheumatology, Rheumatoid Arthritis cohort data
Modern Rheumatology · 2024
DOI: 10.1093/mr/road066 ↗Kurz gefasst
Validierungsstudie in der Zeitschrift Modern Rheumatology, 2024. Verfasst von Tomoaki Higuchi und 12 weiteren Autor:innen. Beteiligte Einrichtung: Division of Rheumatology, Department of Internal Medicine, Tokyo Women's Medical University School of Medicine, Tokyo, Japan. Hauptthemen laut MEDLINE: Arthritis, Rheumatoid, Antirheumatic Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 27 Literaturangaben.
Abstract (Originalsprache)
Objectives
This article aims to examine the ability of the Rheumatoid Arthritis Observation of Biologic Therapy (RABBIT) risk score to predict the occurrence of serious infections in Japanese patients with rheumatoid arthritis (RA), after initiating their first biologic disease–modifying antirheumatic drug (bDMARD).
Methods
We used data from the Institute of Rheumatology, Rheumatoid Arthritis cohort from 2008 to 2020. Patients with RA who were started on their first bDMARDs were included. Those with missing data required to calculate the score were excluded. A receiver operating characteristic curve was used to evaluate the discriminatory ability of the RABBIT score.
Results
A total of 1081 patients were enrolled. During the 1-year observational period, 23 (1.7%) patients had serious infections; the most frequent one was bacterial pneumonia (n = 11, 44%). The median RABBIT score in the serious infection group was significantly higher than that in the non-serious infection group [2.3 (1.5–5.4) vs 1.6 (1.2–2.5), P < .001]. The area under the receiver operating characteristic curve for the occurrence of serious infections was 0.67 (95% confidence interval 0.52–0.79), suggesting that the score had low accuracy.
Conclusions
Our present study revealed that the RABBIT risk score did not have sufficient discriminatory ability for predicting the development of severe infections in Japanese patients with RA after initiating their first bDMARD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Rheumatology, Department of Internal Medicine, Tokyo Women's Medical University School of Medicine, Tokyo, Japan.
- Division of Multidisciplinary Management of Rheumatic Diseases, Department of Internal Medicine, Tokyo Women's Medical University School of Medicine, Tokyo, Japan.
- Showa University Research Administration Centre, Showa University, Tokyo, Japan.
- Department of Orthopaedic Surgery, Tokyo Women's Medical University School of Medicine, Tokyo, Japan.
- Department of Rheumatology, Sanno Medical Centre, Tokyo, Japan.
ORCID-Profile: Eiichi Tanaka
Zitieren
APA
Higuchi, T., Tanaka, E., Inoue, E., Abe, M., Saka, K., Sugano, E., Sugitani, N., Higuchi, Y., Ochiai, M., Yamaguchi, R., Ikari, K., Yamanaka, H., & Harigai, M. (2024). Evaluation of the Rheumatoid Arthritis Observation of Biologic Therapy risk score in Japanese patients with rheumatoid arthritis starting first biologic disease–modifying antirheumatic drugs: A validation study using the Institute of Rheumatology, Rheumatoid Arthritis cohort data. Modern Rheumatology. https://doi.org/10.1093/mr/road066
Vancouver
Higuchi T, Tanaka E, Inoue E, Abe M, Saka K, Sugano E, et al. Evaluation of the Rheumatoid Arthritis Observation of Biologic Therapy risk score in Japanese patients with rheumatoid arthritis starting first biologic disease–modifying antirheumatic drugs: A validation study using the Institute of Rheumatology, Rheumatoid Arthritis cohort data. Modern Rheumatology. 2024. doi:10.1093/mr/road066
BibTeX
@article{Higuchi2024,
author = {Higuchi, Tomoaki and Tanaka, Eiichi and Inoue, Eisuke and Abe, Mai and Saka, Kumiko and Sugano, Eri and Sugitani, Naohiro and Higuchi, Yoko and Ochiai, Moeko and Yamaguchi, Rei and Ikari, Katsunori and Yamanaka, Hisashi and Harigai, Masayoshi},
title = {Evaluation of the Rheumatoid Arthritis Observation of Biologic Therapy risk score in Japanese patients with rheumatoid arthritis starting first biologic disease–modifying antirheumatic drugs: A validation study using the Institute of Rheumatology, Rheumatoid Arthritis cohort data},
journal = {Modern Rheumatology},
year = {2024},
doi = {10.1093/mr/road066}
}
EUVIMED